Revive
Therapeutics Announces Research Collaboration with
North
Carolina State University for Natural
Biosynthesis Enzymatic Platform To
Develop Psilocybin
TORONTO, Jan.
14th,
2021 -- InvestorsHub
NewsWire -- Revive
Therapeutics Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF), a specialty life sciences company
focused on the research and development of therapeutics for medical
needs and rare disorders, is pleased to announce it has entered
into a sponsored
research
agreement and an exclusive option to license agreement with North
Carolina State University ("NC
State") to develop a
novel biosynthetic version of psilocybin based on a natural
biosynthesis enzymatic platform developed by Dr. Gavin Williams,
Professor and Researcher at NC
State.
The
biosynthetic platform developed by Dr. Gavin
Williams
provides a potential simple and efficient method for rapidly
producing natural products, such as psilocybin, using an engineered
enzymatic pathway in E.
coli.
Revive
seeks to develop and commercialize its own pharmaceutical-grade
psilocybin with this biosynthesis technology at scale to support
the Company's current psilocybin-based product pipeline that
includes an oral thin film product currently being developed in
collaboration with the University of Wisconsin-Madison and the
intellectual property and research with psilocybin being developed
by PharmaTher
Inc.
(CSE: PHRM, OTCQB:
PHRRF).
"We are
excited to partner with NC State
and
work with Dr. Williams and his team to develop a proprietary form
of psilocybin that can be produced at scale for research and
commercial purposes while allowing us to create our own unique
product offerings with psilocybin in different delivery methods so
as to treat the various mental health conditions and other diseases
that psilocybin has shown to be a potential viable treatment option
for" said Michael Frank, CEO of Revive. "We continue to
expand our psychedelic pharmaceutical objectives in specializing in
novel products and uses of psilocybin for unmet medical
needs."
Dr.
Williams and his team recently developed an artificial enzymatic
platform called the 'Alcohol Dependent Hemiterpene' pathway for
construction of alkyl pyrophosphates. Here, the products of
the
ADH
pathway will be
used to
generate key building blocks for psilocybin and its
derivatives. The
goal is
to engineer E.
coli to be a factory for
psilocybin production, using a completely artificial biosynthetic
logic.
Dr.
Gavin Williams is Professor and Associate Head of the Department of
Chemistry and named LORD Corporation Distinguished Scholar
at NC
State. Dr.
Williams is a decorated chemist and is well-known for his
innovative work in polyketide biosynthesis, the development of
enzymatic tools for protein engineering, and the development of
novel biosensors to guide metabolic engineering and
high-throughput synthetic biology. His research lab has an
interest in combining the power of biology and organic chemistry to
provide access to new complex organic molecules. More specifically,
Williams Lab leverages enzyme engineering, biocatalysis, metabolic
engineering, organic chemistry, and synthetic biology to access and
diversify the structures of natural products, which forms an
innovative and powerful platform for drug development
and discovery.
About
Revive Therapeutics Ltd.
Revive
is a life sciences company focused on the research and development
of therapeutics for infectious diseases and rare disorders, and it
is prioritizing drug development efforts to take advantage of
several regulatory incentives awarded by the FDA such as Orphan
Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive's
cannabinoid
pharmaceutical portfolio focuses on rare inflammatory diseases and
the company was granted FDA orphan drug status designation for the
use of Cannabidio
(CBD)
to treat autoimmune hepatitis (liver disease) and to treat ischemia
and reperfusion injury from organ transplantation. For more
information, visit
www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation
Services Provider has reviewed or accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on
Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the Offering, including the
intended use of proceeds. Forward-looking information is based on
reasonable assumptions that have been made by Revive at the date of
the information and is subject to known and
unknown risks, uncertainties, and other factors that may cause
actual results or events to differ materially from those
anticipated in the forward-looking information. Given these risks,
uncertainties and assumptions, you should not unduly rely on these
forward-looking statements. The forward-looking information
contained in this press release is made as of the date hereof, and
Revive is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise, except as required by applicable securities laws. The
foregoing statements expressly qualify any forward-looking
information contained herein. Reference is made to the risk factors
disclosed under the heading "Risk Factors" in the Company's annual
MD&A for the fiscal year ended June 30, 2020, which has been
filed on SEDAR and is available under the Company's profile
at www.sedar.com.
